Total Payments
$2.0M
2024 Payments
$280,967
Companies
37
Transactions
1,392
Medicare Patients
2,019
Medicare Billing
$211,340
Payment Breakdown by Category
Other$1.6M (81.6%)
Consulting$170,700 (8.6%)
Travel$165,962 (8.4%)
Food & Beverage$24,025 (1.2%)
Research$2,655 (0.1%)
Education$339.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 637 | 74.0% |
| Consulting Fee | $170,700 | 69 | 8.6% |
| Travel and Lodging | $165,962 | 335 | 8.4% |
| Honoraria | $134,985 | 72 | 6.8% |
| Food and Beverage | $24,025 | 256 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $14,910 | 7 | 0.8% |
| Unspecified | $2,655 | 5 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.0% |
| Education | $339.60 | 10 | 0.0% |
Payments by Type
General
$2.0M
1,387 transactions
Research
$2,655
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $182,728 | 144 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $179,395 | 125 | $0 (2023) |
| GENZYME CORPORATION | $168,477 | 115 | $0 (2024) |
| Seagen Inc. | $152,764 | 92 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $136,574 | 114 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $131,736 | 91 | $0 (2024) |
| Janssen Biotech, Inc. | $128,946 | 104 | $0 (2024) |
| Celgene Corporation | $124,024 | 97 | $0 (2021) |
| SOBI, INC | $112,945 | 53 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $101,943 | 52 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $280,967 | 171 | SOBI, INC ($80,278) |
| 2023 | $404,496 | 269 | Janssen Biotech, Inc. ($47,902) |
| 2022 | $297,487 | 187 | E.R. Squibb & Sons, L.L.C. ($41,983) |
| 2021 | $237,192 | 161 | Karyopharm Therapeutics Inc. ($43,761) |
| 2020 | $154,814 | 104 | Novartis Pharmaceuticals Corporation ($26,147) |
| 2019 | $222,401 | 167 | Novartis Pharmaceuticals Corporation ($62,709) |
| 2018 | $195,838 | 167 | Novartis Pharmaceuticals Corporation ($52,444) |
| 2017 | $184,212 | 166 | GENZYME CORPORATION ($41,882) |
All Payment Transactions
1,392 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,012.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,087.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,181.70 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $121.68 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $117.25 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/05/2024 | EMD Serono, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $765.00 | General |
| 12/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,012.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/21/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $414.03 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/21/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $321.87 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/21/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $113.02 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Honoraria | Cash or cash equivalent | $4,715.00 | General |
| Category: Genetically Defined Disease | ||||||
| 11/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $693.95 | General |
| Category: Genetically Defined Disease | ||||||
| 11/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $438.60 | General |
| Category: Genetically Defined Disease | ||||||
| 11/07/2024 | SOBI, INC | VONJO (Drug) | Travel and Lodging | Cash or cash equivalent | $40.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/07/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $38.38 | General |
| Category: Genetically Defined Disease | ||||||
| 11/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,005.00 | General |
| 11/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $124.93 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AZA-MDS-006 | Celgene Corporation | $1,488 | 2 |
| A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER | Eli Lilly and Company | $1,167 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 379 | 458 | $173,856 | $36,673 |
| 2022 | 9 | 569 | 759 | $281,422 | $63,222 |
| 2021 | 9 | 549 | 782 | $278,590 | $64,739 |
| 2020 | 9 | 522 | 735 | $242,203 | $46,706 |
Total Patients
2,019
Total Services
2,734
Medicare Billing
$211,340
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 96 | 127 | $55,499 | $12,823 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 137 | 181 | $58,644 | $11,692 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $22,572 | $4,280 | 19.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 53 | 57 | $12,540 | $2,181 | 17.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $8,060 | $1,784 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,792 | $1,536 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $6,474 | $1,374 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 15 | $4,275 | $1,003 | 23.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 128 | 194 | $84,778 | $20,546 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 181 | 245 | $79,380 | $16,581 | 20.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 52 | 52 | $32,604 | $7,068 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 81 | 89 | $19,580 | $4,020 | 20.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 45 | $14,355 | $3,658 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 41 | 41 | $20,418 | $3,597 | 17.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 47 | $10,387 | $2,638 | 25.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 21 | $8,820 | $2,260 | 25.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 14 | $8,680 | $2,207 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $2,420 | $645.49 | 26.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 102 | 160 | $69,920 | $18,116 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 158 | 257 | $83,268 | $18,042 | 21.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 132 | 160 | $35,200 | $7,336 | 20.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 64 | $20,416 | $5,298 | 26.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 48 | 48 | $23,904 | $4,990 | 20.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $18,183 | $4,187 | 23.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 23 | $14,260 | $3,701 | 26.0% |
About Dr. Daniel Landau, MD
Dr. Daniel Landau, MD is a Hematology & Oncology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1780712372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Landau, MD has received a total of $2.0M in payments from pharmaceutical and medical device companies, with $280,967 received in 2024. These payments were reported across 1,392 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Landau has provided services to 2,019 Medicare beneficiaries, totaling 2,734 services with total Medicare billing of $211,340. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Orlando, FL
- Active Since 03/02/2007
- Last Updated 10/13/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1780712372
Products in Payments
- IMBRUVICA (Drug) $125,831
- PADCEV (Biological) $124,891
- CALQUENCE (Drug) $115,213
- XPOVIO (Drug) $101,943
- JEVTANA (Drug) $99,993
- Revlimid (Drug) $93,596
- VONJO (Drug) $78,428
- OPDIVO (Biological) $71,308
- PROMACTA (Drug) $63,529
- ADCETRIS (Biological) $60,464
- Imbruvica (Drug) $58,393
- EMPLICITI (Biological) $57,241
- Cabometyx (Drug) $55,618
- JAKAFI (Drug) $50,565
- Nubeqa (Drug) $44,062
- Pomalyst (Drug) $42,188
- DARZALEX (Biological) $40,259
- CABOMETYX (Drug) $36,477
- ENJAYMO (Biological) $33,927
- Doptelet (Drug) $30,817
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Orlando
Dr. Mark Socinski, Md, MD
Hematology & Oncology — Payments: $3.1M
Hematology & Oncology $3.1M
Tarek Mekhail, M.d, M.D
Hematology & Oncology — Payments: $2.7M
Hematology & Oncology $2.7M
Sajeve Thomas, Md, MD
Hematology & Oncology — Payments: $843,415
Hematology & Oncology $843,415
Rebecca Moroose, Md, MD
Hematology & Oncology — Payments: $790,811
Hematology & Oncology $790,811
Dr. Nikita Shah, Md, MD
Hematology & Oncology — Payments: $493,804
Hematology & Oncology $493,804
Dr. Guru Sonpavde, Md, MD
Hematology & Oncology — Payments: $425,119
Hematology & Oncology $425,119